Merck's Keytruda Study Shows Improvement for Patients Who Also Use Chemotherapy
January 06 2020 - 5:08PM
Dow Jones News
By Kimberly Chin
Merck & Co. (MRK) said that an advanced trial of its cancer
treatment Keytruda met one of its primary endpoints showing
significant improvement in patients who used the drug in
conjunction with chemotherapy.
The study offered first-line treatment of patients with
extensive-stage, small-cell lung cancer. The company said the
trial's results show that the combination had a significant
improvement on patients compared with chemotherapy alone.
However, Merck said it didn't meet its other primary endpoint
for a patient's overall survival, deeming results had little to no
"statistical significance."
Keytruda is an anti-PD-1 therapy that helps increase the body's
immune system so that it can detect and fight tumor cells. Merck is
testing the treatment across multiple settings and stages of lung
cancer.
Shares of Merck were off slightly by 0.7% at $90.99 in
after-hours trading.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
January 06, 2020 16:53 ET (21:53 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024